Payment overview · 2025
General Payments
$341.18
17 reported records · 8 companies
Healthcare provider profile · identity verified
Jacob Carpenter, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LANCASTER, CA · NPI 1295199263
Verified facts
What the public records show
CMS Open Payments records show Jacob Carpenter, FNP-C received $341.18 in general payments during 2025 across 17 reported records.
Lilly USA, LLC accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $87.11 | 25.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.21 | 17.9% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $60.08 | 17.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.51 | 11.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.84 | 11.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.23 | 5.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.67 | 5.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.53 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $341.18 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.11 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.21 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.21 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $60.08 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.71 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 152 |
| Gabapentin | Gabapentin | 267 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 264 | 97 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 263 | 101 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 248 | 68 |
| Losartan Potassium | Losartan Potassium | 237 | 79 |
| Lisinopril | Lisinopril | 185 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 181 | 60 |
| Omeprazole | Omeprazole | 171 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 64 |
| Trazodone Hcl | Trazodone Hcl | 167 | 49 |
| Furosemide | Furosemide | 154 | 59 |
| Metformin Hcl | Metformin Hcl | 154 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 67 |
| Diclofenac Sodium | Diclofenac Sodium | 133 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 47 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 40 |
| Meloxicam | Meloxicam | 116 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 41 |
| Azithromycin | Azithromycin | 102 | 90 |
| Glipizide | Glipizide | 101 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 38 |
| Ibuprofen | Ibuprofen | 100 | 40 |
| Famotidine | Famotidine | 99 | 36 |
| Tramadol Hcl | Tramadol Hcl | 94 | 38 |
| Carvedilol | Carvedilol | 86 | 27 |
| Baclofen | Baclofen | 78 | 23 |
| Januvia | Sitagliptin Phosphate | 78 | 30 |
| Sertraline Hcl | Sertraline Hcl | 74 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 73 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 14 |
| Allopurinol | Allopurinol | 67 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 30 |
| Mupirocin | Mupirocin | 66 | 41 |
| Potassium Chloride | Potassium Chloride | 62 | 21 |
| Clonidine Hcl | Clonidine Hcl | 61 | 21 |
| Cephalexin | Cephalexin | 60 | 54 |
| Ozempic | Semaglutide | 59 | 19 |
| Montelukast Sodium | Montelukast Sodium | 58 | 20 |
| Prednisone | Prednisone | 58 | 49 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 47 |
| Jardiance | Empagliflozin | 56 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 26 |
| Simvastatin | Simvastatin | 55 | 27 |
| Alprazolam | Alprazolam | 54 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 43 |
| Eliquis | Apixaban | 53 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 15 |
| Lorazepam | Lorazepam | 52 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 40 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 41 |
| Ciclopirox | Ciclopirox | 47 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | 17 |
| Benazepril Hcl | Benazepril Hcl | 44 | 15 |
| Fenofibrate | Fenofibrate | 43 | 17 |
| Ezetimibe | Ezetimibe | 42 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 14 |
| Naproxen | Naproxen | 38 | 17 |
| Clotrimazole | Clotrimazole | 36 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 11 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | 12 |
| Fluconazole | Fluconazole | 31 | 15 |
| Nitroglycerin | Nitroglycerin | 31 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 11 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 22 |
| Olanzapine | Olanzapine | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 15 |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 13 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | 12 |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $341.18 · 17 records | Lilly USA, LLC | ACCRUFER, CAPLYTA, FREESTYLE LIBRE 3, Korlym, MOUNJARO, OTEZLA, REPATHA, REXULTI, Wegovy, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error